Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 10, 2008Neurology

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

View Full Paper
Ask AI
Bookmark
Share

Authors

JEJamie L. EberlingMichael J. Fox Foundation
William J. Jagust
William J. JagustBoston UniversityCCChadwick W. ChristineUniversity of California, San Francisco

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Eberling et al. (2008) studied this question.

synapsesocial.com/papers/69177fdcedb60db7ff7f1871https://doi.org/10.1212/01.wnl.0000312381.29287.ff
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations1985 · 1,715 citations
  2. 2Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC2006 · 282 citations
  3. 3Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy1990 · 628 citations
  4. 4Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies1987 · 134 citations